Article

Increased dosage of wild-type KRAS protein drives <i>KRAS</i> -mutant lung tumorigenesis and drug resistance

2024-03-01

Abstract excerpt

Almost 30% of lung adenocarcinomas are driven by activating KRAS mutations. The heterogeneous clinical behavior observed in these cancers could be due to the imbalance of wild-type and oncogenic KRAS alleles. However, the role of RAS dysregulation at the protein level needs to be further explored. A genome-wide global protein stability screen identified the CUL3 ubiquitin ligase adaptor LZTR1, as a major proteost...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5a273d86-4742-57dd-9803-8ee6de0ca850
DOI: 10.1101/2024.02.27.582346

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Increased dosage of wild-type KRAS protein drives <i>KRAS</i> -mutant lung tumorigenesis and drug resistanceDOI 10.1101/2024.02.27.582346Read

Alveolar differentiation drives resistance to KRAS inhibition in lung adenocarcinomaSemantic proximity Read

Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors.Semantic proximity Read

Genetic identification of the RAS proteostatic machinery and its failure to regulate oncogenic variantsSemantic proximity Read

Mutant <i>KRAS</i> dosage contributes to heterogeneity in lung cancer therapeutic responseSemantic proximity Read

A cellular and spatial atlas of <i>TP53</i> -associated tissue remodeling in lung adenocarcinomaSemantic proximity Read

Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.Semantic proximity Read

Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancerSemantic proximity Read

Inhibition of ULK1/2 and KRAS <sup>G12C</sup> controls tumor growth in preclinical models of lung cancerSemantic proximity Read

Multiplexed identification of RAS paralog imbalance as a driver of lung cancer growthSemantic proximity Read

UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinomaSemantic proximity Read

KRASG12V Degraders Provide a Potential Therapeutic Opportunity in Lung Adenocarcinoma.Semantic proximity Read

Multiplexed identification of RAS paralog imbalance as a driver of lung cancer growthSemantic proximity Read